© 2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. EMD Serono, Inc. is the healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada.
We are investigating the role that acquired resistance due to MET amplification may have across tumor types, and how that can potentially be targeted through combination therapies
TARGETS UNDER INVESTIGATION
Abbreviations:
MET, mesenchymal-epithelial transition proto-oncogene.
